Silvia Crescioli, PhD.

Dr. Silvia Crescioli is a Consultant for The Antibody Society and chair of The Antibody Society Communication and Membership Committee. Since 2021 she has co-authored the “Antibodies to watch” articles in published in mAbs, reviewing recently approved antibody therapeutics, and forecasting antibody therapeutics marketing application submission as well as approvals that might occur the following year. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence in 2014, followed by eight years as a post doc at King’s College London in Prof. Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she is now a visiting Research Fellow. Her research interests focus on antibody therapeutics development for both cancer and noncancer indications, as well as on different areas of cancer immunology and immunotherapy, including antibody discovery, antibody engineering and glycoengineering.